×
About 132,708 results

ALLMedicine™ Type 2 Diabetes Center

Research & Reviews  42,478 results

Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recomm...
https://doi.org/10.1001/jama.2021.12531
JAMA , Davidson KW et. al.

Aug 25th, 2021 - An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes...

Metformin effect in models of inflammation is associated with activation of ATP-depende...
https://doi.org/10.1007/s10787-021-00899-4 10.1038/s41393-018-0168-x 10.3945/jn.113.183657 10.1016/j.ejphar.2019.172497 10.1002/pdi.606 10.1152/ajpgi.00329.2014 10.1152/ajplung.00389.2014 10.1016/j.it.2017.12.003 10.1111/j.1475381.1971.tb07124.x 10.1182/blood-2013-02-486217 10.1111/j.2042-7158.1972.tb08940.x 10.1006/cyto.2000.0816 10.1006/cyto.2001.0980 10.1080/10739680802355897 10.18632/aging.102453 10.1007/s10787-016-0275-2 10.1073/pnas.1221055110 10.1073/pnas.1106201108 10.1016/j.intimp.2013.03.020 10.1055/s-0030-1255033 10.4049/jimmunol.167.1.524 10.1371/journal.pone.0135858 10.1007/s00380-008-1137-7 10.1007/s00011-012-0504-0 10.4103/0253-7613.157127 10.1016/j.ejphar.2015.11.034 10.1016/j.bcp.2012.09.025 10.2119/molmed.2013.00065 10.1213/ANE.0000000000001561 10.1038/sj.bjp.0705650 10.3892/mmr.2016.4821 10.1016/j.jpain.2013.05.012 10.2174/1871530315666150316124019 10.1016/j.neuroscience.2014.05.031 10.1016/j.bpa.2003.12.002 10.1016/j.nbd.2017.06.001 10.2337/db14-1225 10.1159/000087655 10.1172/JCI14178 10.1016/j.intimp.2012.01.015 10.1172/JCI13505 10.1016/0304-3959(83)90201-4
Inflammopharmacology Augusto PSA, Matsui TC et. al.

Dec 2nd, 2021 - Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus. We have recently demonstrated that metformin exhibits activity in models of nociceptive and neuropathic pain. However, little is known about its effe...

Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 D...
https://doi.org/10.1007/s11606-021-07227-0 10.2337/dc21-S009
Journal of General Internal Medicine; Alexander JT, Staab EM et. al.

Dec 2nd, 2021 - Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) are a recent class of medication approved for the treatment of type 2 diabetes (T2D). Previous meta-analyses have quantified the benefits and harms of SGLT2Is; however, these analyses have been l...

Revisiting the Strategies for the Pharmacological Management of Type 2 Diabetes- from G...
https://doi.org/10.1111/jdi.13726
Journal of Diabetes Investigation; Li HY

Dec 2nd, 2021 - The goals of diabetes care are to prevent complications and optimize quality of life. Based on the goals, several strategies have developed and are still evolving for the pharmacological management of type 2 diabetes. In the last decade, various n...

Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data ...
https://doi.org/10.1210/clinem/dgab832
The Journal of Clinical Endocrinology and Metabolism; Islam N, Nash R et. al.

Dec 2nd, 2021 - Risk of type 2 diabetes mellitus (T2DM) in transgender and gender diverse (TGD) persons, especially those receiving gender affirming hormone therapy (GAHT) is an area of clinical and research importance. We used data from an electronic health reco...

see more →

Guidelines  53 results

Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recomm...
https://doi.org/10.1001/jama.2021.12531
JAMA , Davidson KW et. al.

Aug 25th, 2021 - An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes...

Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation St...
https://doi.org/10.1001/jama.2021.11922
JAMA , Davidson KW et. al.

Aug 11th, 2021 - Gestational diabetes is diabetes that develops during pregnancy. Prevalence of gestational diabetes in the US has been estimated at 5.8% to 9.2%, based on traditional diagnostic criteria, although it may be higher if more inclusive criteria are us...

Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary ...
https://doi.org/10.1016/j.numecd.2021.04.014
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Chiodini I, Gaudio A et. al.

Jun 2nd, 2021 - Bone fragility is increasingly recognized as a relevant complication of type 2 diabetes (T2D) and diabetic patients with fragility fractures have higher mortality rates than non diabetic individuals or diabetic patients without fractures. However,...

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 9th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES...
https://doi.org/10.1016/j.numecd.2020.08.021
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Moghetti P, Balducci S et. al.

Oct 2nd, 2020 - Regular exercise is considered a cornerstone in the management of type 2 diabetes mellitus (T2DM). It improves glucose control and cardiovascular risk factors, contributes to weight loss, and also improves general well-being, likely playing a role...

see more →

Drugs  1,400 results see all →

Clinicaltrials.gov  2,654 results

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
https://clinicaltrials.gov/ct2/show/NCT04770532

Nov 25th, 2021 - This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken we...

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04591626

Nov 25th, 2021 - The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Ty...
https://clinicaltrials.gov/ct2/show/NCT04880850

Nov 25th, 2021 - This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken we...

Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT04924777

Nov 25th, 2021 - To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more si...

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
https://clinicaltrials.gov/ct2/show/NCT05134662

Nov 25th, 2021 - This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in overweight and obese su...

see more →

News  6,471 results

Type 2 diabetes remission can happen naturally in 1 in 20
https://www.mdedge.com/endocrinology/article/249002/diabetes/type-2-diabetes-remission-can-happen-naturally-1-20
Mitchel L. Zoler, PhD

Nov 22nd, 2021 - Roughly 5% of adults with type 2 diabetes achieve remission of their disease, often unbeknownst to the patient and without aggressive weight-loss interventions, according to a new analysis of data from more than 160,000 people in a national diabet.

Case: Older patient with T2D has recurrent flushing
https://www.mdedge.com/internalmedicine/article/248875/geriatrics/case-older-patient-t2d-has-recurrent-flushing
Douglas S. Paauw, MD

Nov 18th, 2021 - A 64 year-old man with type 2 diabetes complains of recurrent flushing for the past 6 months. He has had no other symptoms.

Continuous Ketone Monitoring Has Potential to Cut DKA in Diabetes
https://www.medscape.com/viewarticle/963120

Nov 17th, 2021 - The development of an on-body continuous ketone monitor (CKM) is seen as potentially helpful for the prevention of diabetic ketoacidosis (DKA) and other clinical situations. Speakers at two meetings held this month have addressed the potential use...

Europe Gives Green Light to Once-Weekly Semaglutide for Weight Loss
https://www.medscape.com/viewarticle/963027

Nov 16th, 2021 - Once-weekly semaglutide 2.4 mg injection (Wegovy, Novo Nordisk) has been granted a positive opinion in the European Union for weight management in people with obesity or those who are overweight with one or more weight-related conditions. The spec...

Call for Tighter LDL Targets for Highest Risk Patients
https://www.medscape.com/viewarticle/962914

Nov 15th, 2021 - LONDON - Tighter low-density lipoprotein (LDL) targets, should be the aim in very high-risk patients, using a combination of therapies in a new era of ‘ones not twos’ (in terms of mmol/L), according to experts in lipid and cardiovascular risk mana...

see more →

Patient Education  27 results see all →